ConductScience.org, home

Library / Trials

Social Media Perceptions Among Young Adults With Cancer - Online Experiment 2

NCT07928349, Not applicable, Completed, UNC Lineberger Comprehensive Cancer Center

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleSocial Media Perceptions Among Young Adults With Cancer - Online Experiment 2ClinicalTrials.gov
NCT numberNCT07928349ClinicalTrials.gov
StatusCompletedClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment207 participants, actualClinicalTrials.gov
Lead sponsorUNC Lineberger Comprehensive Cancer CenterClinicalTrials.gov
ConditionsCancer, Cancer SurvivorsClinicalTrials.gov
InterventionsCancer Peer and Clinician Messages, Public Service Announcement MessagesClinicalTrials.gov
First posted2026-11-10ClinicalTrials.gov
Last updated2026-11-10ClinicalTrials.gov

Registered outcomes 5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryPerceived Message Effectiveness for In-Person Interactions (Single-Item Self-Report, 5-Point Scale)Baseline, Up to 1 hour
After viewing each of 9 social media posts, participants answered one item: "How much does this post make you want to interact in person with people you barely know? (This doesn't include online interactions.)" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived message effectiveness for in-person interactions. Ratings were compared across experimental conditions and message types.
ClinicalTrials.gov
SecondaryPositive Affect (Single-Item Self-Report, 5-Point Scale)Baseline, Up to 1 hour
After viewing each of 9 social media posts, participants answered one item: "How good does viewing this post make you feel?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater positive affect. Ratings were compared across experimental conditions and message types.
ClinicalTrials.gov
SecondaryPerceived Social Presence (single item adapted from Lazard et al., 2020; 5-point agreement scale)Baseline, Up to 1 hour
After viewing each of 9 social media posts, participants answered one item: "When viewing this post, how much do you feel as if someone is talking to you?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived social presence. Ratings were compared across experimental conditions and message types.
ClinicalTrials.gov
SecondaryMessage Relevance (Single Item Adapted From Jensen et al., 2024; 5-Point Scale)Baseline, Up to 1 hour
After viewing each of 9 social media posts, participants answered one item: "How relevant is this post to you?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived relevance. Ratings were compared across experimental conditions and message types.
ClinicalTrials.gov
SecondaryPerceived Message Effectiveness for Online Interactions (Single-Item Self-Report, 5-Point Scale)Baseline, Up to 1 hour
After viewing each of 9 social media posts, participants answered one item: "How much does this post make you want to interact online with people you barely know? (Online includes on social media.)" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived message effectiveness for online interactions. Ratings were compared across experimental conditions and message types.
ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)